Clinical Trials Logo

THC clinical trials

View clinical trials related to THC.

Filter by:

NCT ID: NCT06378957 Not yet recruiting - THC Clinical Trials

Behavioral Pharmacology of Orally Administered THC and D-limonene

Start date: September 1, 2024
Phase: Phase 1
Study type: Interventional

The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.

NCT ID: NCT06099379 Not yet recruiting - Cannabis Clinical Trials

Modulation of THC Effects by CBD: a Dose-ranging Study

SPECTRE
Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.

NCT ID: NCT06077292 Not yet recruiting - Clinical trials for Cognitive Impairment

Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults

THC-YA
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25. The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline? Other questions this study aims to answer include: - Can researchers accurately assess THC consumption among frequent cannabis users? - Can researchers effectively incentivize cannabis users to use less potent THC products? - Do genetic variations in THC metabolism impact urinary THC excretion? - Do genetic variations in THC metabolism impact cognitive performance in cannabis users? - Are quantitative urinary THC values predictive of cognitive impairment? - How can researchers use research findings to inform harm reduction practices for people who use cannabis? Participants will submit blood and urine samples and be incentivized to use less potent THC products.

NCT ID: NCT05999383 Not yet recruiting - Tobacco Use Clinical Trials

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

CANNIC
Start date: October 31, 2023
Phase: Phase 2
Study type: Interventional

This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.

NCT ID: NCT05641766 Not yet recruiting - THC Clinical Trials

Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks

THC-MEG
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to use non-invasive brain imaging methods (MEG and EEG) to characterize the effects of THC on brain activity during learning.

NCT ID: NCT05514899 Recruiting - HIV Clinical Trials

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

CAMI
Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.

NCT ID: NCT05427630 Suspended - Migraine Clinical Trials

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.

NCT ID: NCT05121506 Completed - Clinical trials for Biological Availability

A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults

Start date: November 27, 2021
Phase: Phase 1
Study type: Interventional

The bioavailability of cannabinoids differs greatly for different routes of administration. When applied topically to the skin, they are absorbed through the skin or hair follicles while interacting with receptors to provide localized effects. To gain more information on the potential of this route of administration in therapeutic applications, this open-label study will investigate the skin absorption and bioavailability of CBD and THC delivered trans-dermally.

NCT ID: NCT05116527 Recruiting - Cannabis Clinical Trials

THC Memory & Reward Learning Pilot

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.

NCT ID: NCT04976738 Completed - Pain Clinical Trials

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

CYDEPS
Start date: September 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.